CNS Disorders  >>  methylprednisolone sodium succinate  >>  Phase 2
Welcome,         Profile    Billing    Logout  

3 Trials

Remove FilterRemove FilterRemove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
methylprednisolone sodium succinate / Generic mfg.
NCT01039103 / 2009-013884-21: Nanocort in Acute Exacerbation of Relapsing-Remitting Multiple Sclerosis (MS)

Terminated
2
15
Europe
PEG-liposomal prednisolone sodium phosphate, Nanocort, Methylprednisolone, Solu-Medrol
Galapagos NV
Acute Exacerbation of Remitting Relapsing Multiple Sclerosis, Clinically Isolated Syndrome
11/11
11/11
RESTORE, NCT01071083 / 2009-017490-38: Treatment Interruption of Natalizumab

Checkmark Interim Data AAN (MS)
Mar 2012 - Mar 2012: Interim Data AAN (MS)
Completed
2
175
US, Europe
natalizumab, interferon beta 1-a, methylprednisolone, IV placebo, glatiramer acetate
Biogen, Elan Pharmaceuticals
Relapsing Remitting Multiple Sclerosis
11/11
11/11
INCREASE, NCT03387046: A Pilot Study in Participants With Relapsing Remitting Multiple Sclerosis (RR-MS)

Terminated
2
7
Europe
D-aspartate, Placebo, IFN beta-1a, Methylprednisolone
Merck KGaA, Darmstadt, Germany
Multiple Sclerosis, Relapsing-Remitting
01/19
01/19

Download Options